Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in Relapsed or Refractory DLBCL
NCT04404283Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of brentuximab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Pfizer. Started Aug 2020; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04404283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404283.